Posted on March 1, 2019 by Sitemaster
Back in December 2017, Pfizer started a trial to explore whether the PARP inhibitor talazoparib (Talzenna) could be used in combination with enzalutamide (Xtandi) to effectively treat men with what are known as MSI-H or dMMR subtypes of metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: inhibitor, mCRPC, niraparib, olaparib, PARP, Phase III, rucaparib, talazoparib | 5 Comments »
Posted on February 26, 2019 by Sitemaster
We know that both abiraterone acetate (Zytiga) and enzalutamide (Xtandi) can be used to extend the survival of men with mCRPC who have already been treated with docetaxel + prednisone. However, … READ MORE …
Filed under: Uncategorized | Tagged: castration-resistant, CHEIRON, combination, docetaxel, enzalutamide, mCRPC, metastatic, trial | Leave a comment »
Posted on December 27, 2018 by Sitemaster
A new paper in the Journal of Clinical Oncology has just reported that the overall survival (OS) of black and white men diagnosed with metastatic castration-resistant prostate cancer (mCRPC) seems to be near to identical after treatment with docetaxel or a docetaxel-containing regimen. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: black, castration-resistant, docetaxel, mCRPC, metastatic, race, survival, white | Leave a comment »
Posted on September 25, 2018 by Sitemaster
Posted on February 5, 2018 by Sitemaster
The currently “great unanswered” question in the management of advanced prostate cancer is the order of agents to be used in the treatment of men who are receiving first-line therapy for metastatic prostate cancer after it becomes castration-resistant. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, mCRPC, metastatic, Treatment | 4 Comments »
Posted on January 14, 2018 by Sitemaster
We now have some details from clinical trials of the radiopharmaceutical actinium-225-PSMA-617 (Ac-225-PSMA-617) in very advanced prostate cancer patients. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: actinium-225, mCRPC, PSMA, radiopharmaceutical, trial | 3 Comments »
Posted on January 3, 2018 by Sitemaster
Just over a year ago we wrote up a commentary on this web site entitled, “Can bipolar cycling of testosterone really cure prostate cancer?” It dealt with what is known as “bipolar androgen therapy” or BAT and referred to a Phase II clinical trial known as the RESTORE study. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: androgen, BAT, bipolar, castration-resistant, enzalutamide. metastatic, mCRPC, testosterone, therapy | Leave a comment »
